UCHL5 Antibody

1. Our research reveals a novel mechanism for chromatin occupancy of Tcf7 and highlights the physiological significance of UCHL5 during early vertebrate development by regulating the Wnt/beta-catenin pathway. PMID: 28198400
2. Our studies provide a molecular mechanism by which UCHL5 mitigates TGFbeta-1 signaling through stabilization of Smad2/Smad3. These findings suggest that UCHL5 may contribute to the pathogenesis of idiopathic pulmonary fibrosis and could be a potential therapeutic target. PMID: 27604640
3. Positive cytoplasmic UCHL5 tumor immunoexpression is associated with increased survival in patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p = 0.025), and age 66 years or older (p = 0.037). Therefore, UCHL5 is a potential marker in gastric cancer with significant prognostic relevance. PMID: 29474458
4. Our report demonstrates the significant potential of targeting USP14/UCHL5 with VLX1570 in drug-resistant Waldenstrom macroglobulinemia (WM), suggesting a high potential for clinical translation. PMID: 27813535
5. UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our findings advance the currently limited knowledge of biomarkers in colorectal cancer treatment. PMID: 28681694
6. UCHL5 expression could function as a prognostic marker in pancreatic ductal adenocarcinoma, particularly at disease stages IIB to III. As UCHL5 is one of the few markers predicting increased survival, our results may have clinical relevance. PMID: 28653876
7. These results uncover a novel mechanism for E2F1 transcriptional activation through the removal of its Lys-63-linked ubiquitination by UCHL5. PMID: 26396186
8. UCHL5 comprises two domains: a globular UCH-domain and a fibrous C-terminal tail. The C-terminal residues of UCHL5 are involved in Rpn13 binding. PMID: 21953935
9. Data indicate that ubiquitin thioesterase L5 UCHL5 (UCHL5) comprises a catalytic UCH domain followed by the four-helix (alpha8-alpha11) C-terminal domain. PMID: 25702872
10. High expression of UCHL5 is significantly associated with epithelial ovarian cancer. PMID: 25123264
11. b-AP15, an inhibitor of deubiquitylating enzyme USP14 and UCHL5, induces apoptosis in multiple myeloma and overcomes bortezomib resistance. PMID: 24319254
12. UCHL5 over-expression is associated with hepatocellular carcinoma recurrence. PMID: 23220010
13. UCHL5 is associated with outcome and recurrence of ESCC and can serve as a novel predictor for poor prognosis of esophageal squamous cell carcinoma patients after curative resection. PMID: 22615012
14. A functional proteomic analysis was performed to screen UCHL5-interacting proteins in hepatocellular carcinoma (HCC), and glucose-regulated protein 78 was identified as one interacting with UCHL5. PMID: 21800051
15. Our structures reveal conformationally dynamic parts of the enzyme that may play a role in the structural transition to the more active form. PMID: 21995438
16. Silencing of UCHL5 in A549 cells induced apoptosis. PMID: 21287580
17. UCHL5 interacts with Smads and regulates TGF-beta signalling. PMID: 16027725
18. Upregulation of UCHL5 is associated with Uterine Cervical Neoplasms. PMID: 16402389
19. In the nucleus, UCHL5 is also associated with the human Ino80 chromatin-remodeling complex (hINO80). PMID: 18922472
20. The crystal structure of the UCHL5 catalytic domain (UCH-domain) was determined and compared with that of other UCHs. PMID: 19836345

Show More

Hide All

HGNC: 19678

OMIM: 610667

KEGG: hsa:51377

STRING: 9606.ENSP00000356425

UniGene: Hs.145469